What happened
Shares of Exelixis (NASDAQ:EXEL), a mid-cap biotech company primarily focused on developing therapies to treat cancer, surged 164% during 2016 according to S&P Global Market Intelligence. There appear to be four key reasons why the company had such an incredibly good year despite most drug stocks underperforming.
